of nitric oxide (NO) by free hemoglobin is a crucial event, 20 contributing to both thrombosis and other PNH-related symptoms. Hemoglobin released from RBCs during hemolysis binds to haptoglobin, which is rapidly cleared from the circulation via binding to CD163. 21 When the capacity of this hemoglobin-scavenging protein is saturated, free hemoglobin appears in the circulation and reacts with NO to produce nitrate (NO 3 ) and methemoglobin. 22 In addition, hemolysis releases arginase from RBCs. 23 This enzyme converts L-arginine, the substrate for NO synthesis, to ornithine. A profound degree of NO consumption has been demonstrated in PNH patients. 24 NO is a major regulator of smooth-muscle tonus, influences platelet function, and interacts with components of the coagulation cascade. 25 Decreased NO signaling via cyclic guanosine monophosphate (cGMP) leads to increased smoothmuscle tonus, which can result in typical symptoms of PNH, e.g.
abdominal pain, dysphagia, erectile dysfunction, and pulmonary hypertension. NO depletion also increases platelet aggregation, inhibits disaggregation of aggregated platelets, and induces platelet adhesion, which together with local vasoconstriction contribute to thrombophilia (see Figure 2 ). Recent studies have demonstrated that there is a high incidence of progression to chronic renal insufficiency in patients with PNH. Renal damage in PNH has been associated with chronic hemolysis and subsequent hemosiderosis and/or microvascular thrombosis. 25 Progressive pancytopenia occurs in a proportion of PNH patients. In a recent study of a large cohort of patients in France, the cumulative 10-year incidence of bicytopenia or pancytopenia was 19.2%. 9 In
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Management of Paroxysmal Nocturnal Hemoglobinuria-General Aspects
Until recently, only two general treatment approaches were available:
either stem cell transplantation, which had potential to cure but high treatment-related morbidity/mortality, or symptomatic treatment and prophylaxis of complications, which led to unsatisfactory long-term control of the disease. 1, 31 Thus, there was a need for new treatments to be developed. As the clinical symptoms of PNH are due to increased complement sensitivity of blood cells, inhibition of complement was a logical approach. Eculizumab, a monoclonal antibody that inhibits complement protein C5, is the first and so far only specific complement inhibitor approved for clinical use in PNH.
Stem cell transplantation and eculizumab treatment will be discussed in more detail below.
Therapeutic options for PNH are listed in It is controversial whether blood products for PNH patients should be irradiated. NO reduction leads to increase in fibrinogen split products and thrombinantithrombin complexes 84 Platelet activation by free hemoglobin 85 Inhibition of ADAMTS13 by free hemoglobin 86 Platelet vesiculation/microvesicles 87, 88 Increased membrane prothrombinase complex sites; increased rate of prothrombin conversion
Exposure of internal red blood cell membrane
Increased proportion of activated platelets (due to CD59 deficiency) 89 Detachment of urokinase-type plasminogen activator receptor (urokinase receptor
[CD87]-a GPI-linked protein) 90 and reduced fibrinolytic activity 
U S H E M A T O L O G Y
A substantial subgroup of PNH patients has concurrent AA or will develop AA. Therefore, it must be determined how much of the anemia is due to hemolysis and how much is due to bone marrow failure.
Immunosuppressive treatment as established for AA (antithymocyte globulin, cyclosporine A) can improve the impaired hematopoiesis that occurs in hypoproliferative PNH, but the hemolytic component of the disease is not altered by immunosuppressive therapy. 34, 35 The effect of immunosuppression on the size of the PNH clone is equivocal. Both expansion and decrease, and even disappearance, of PNH cells during immunosuppression have been observed. 11, 35, 36 Androgens have been successfully used to treat anemia in PNH. 9, 14 Corticosteroids can be used to attenuate hemolytic exacerbations;
however, only some patients respond to steroids. 14,37-39 Given the inconsistent response and their toxicity profile, it is debatable whether corticosteroids and androgens should be used for long-term treatment. 1 Careful evaluation in terms of convincing evidence for beneficial effects in the individual patient is necessary, and monitoring is essential.
Levels of erythropoietin and granulocyte-colony-stimulating factor (G-CSF) are markedly elevated in PNH. 40, 41 Therefore, it has been questioned whether there is an indication for growth factors in PNH treatment at all; 40 however, in some patients improvement of anemia could be achieved by treatment with erythropoietin. 38, [42] [43] [44] [45] In anecdotal cases, the course of GPI-AP-deficient cells suggests that the efficacy of erythropoietin can be due to either a preferential action on normal cells or the GPI-deficient erythroid clone. 42, 44 In particular, erythropoietin may be a suitable adjunct in patients who have reduced hemolysis during eculizumab treatment (see below), but who are still transfusion-dependent. 46 In patients with hypoplastic PNH, a combination of G-CSF and cyclosporin can improve cytopenia and reduce the number of GPI-APdeficient cells. 47 In eculizumab-treated patients with reduced hemolysis who are still transfusion-dependent, promotion of erythropoiesis by addition of erythropoiesis-stimulating factors may further improve hemoglobin and render patients transfusion-independent, in particular in PNH with underlying bone marrow failure. 46 Other approaches so far Unsatisfactory results are not due to relapse of PNH, which is a very rare event (see Tables 3 and 4) . Transplant-related mortality is the major problem that needs to be addressed. In particular, future studies must address indications for stem cell transplantation, optimization of conditioning regimens, and donor selection. Eculizumab has been evaluated in three separate trials in PNH patients. [70] [71] [72] [73] [74] [75] The first pilot study enrolled 11 patients with hemolytic PNH, 71, 75 and two phase III trials enrolled another 184 patients. 70, 72 The first phase III trial, TRIUMPH, was a double-blind, randomized, placebocontrolled, multicenter trial that examined safety and efficacy in hemolytic PNH patients who had received at least four transfusions in the four months prior to enrolment and a platelet count >100x10 9 /l. 74 SHEPHERD was an open-label, non-placebo-controlled trial that examined eculizumab in a more heterogenous PNH patient population. 70 Patients were required to have received at least one transfusion in the previous two years. A platelet count of ≥30x10 9 /l was In all trials, a significant reduction of hemolysis as measured by LDH was observed across all treated participants. The reduction was observed after one week of treatment and was maintained throughout the whole treatment period. Control of chronic hemolysis in the PNH patients resulted in a decrease in transfusion requirements. In the TRIUMPH and SHEPHERD trials, 51% of patients achieved transfusion independence, and in both trials the transfusion requirements decreased significantly.
Disease-modifying Treatment-Eculizumab
In eculizumab-treated patients in whom transfusion independence was not achieved, transfusion requirements were reduced by 44% (data from TRIUMPH study). 74 The reduction in intravascular hemolysis in the eculizumab group resulted in an increase in PNH type III erythrocytes, whereas the proportion of PNH type III granulocytes and monocytes did not change significantly. 70, 73, 74 This means that a higher proportion of erythrocytes is vulnerable against complement-mediated lysis. In 16
patients from the clinical trial who discontinued eculizumab for various reasons, no serious rebound hemolysis was observed. However, patients should be closely monitored for at least eight weeks in cases of eculizumab discontinuation.
As eculizumab does not block the early stages of complement activation, C3 cleavage products are formed and bind to CD55/CD59-deficient RBCs.
The inhibition of terminal membrane attack complex formation by eculizumab allows the survival of these cells, which otherwise would undergo a rapid intravascular hemolysis due to C5b-9 formation. A positive direct antiglobulin test due to C3d loading (and in some cases also C3c loading of PNH RBCs) seems to be a consistent finding during eculizumab treatment. 92 This explains mild ongoing hemolysis via extravascular sequestration of RBCs loaded with C3 cleavage product. 92 Normalization of hemoglobin after splenectomy in a patient with eculizumab treatment and ongoing extravasal hemolysis has been reported. 76 The immediate and sustained improvement in hemolysis had an impact on fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue instrument: fatigue improved within one week 
of eculizumab treatment and this was maintained throughout the entire study period. The improvement of fatigue in the eculizumab-treated patients was observed regardless of baseline LDH levels. 73 The eculizumab-treated patients also had significant improvements in terms of the European Organization for Research and Treatment of Cancer Core Questionnaire Quality of Life Questionnaires (EORTC QLQ-C30) on the scale for global health status, as well as in scales for functioning (role, social, cognitive, physical, and emotional functioning scale) and in two symptom scales (fatigue, pain). 70, 74 These improvements occurred without complete resolution of anemia. Furthermore, patients who did not achieve complete transfusion independence during eculizumab treatment experienced significant improvements in quality of life and fatigue. 73 This provides further evidence that the diminished quality of life in PNH is also due to intravascular hemolysis and does not just reflect the severity of anemia.
In general, eculizumab was safe and well tolerated. Recently, a desquamating rash and hyperammonemia was reported in a patient following the first administration of eculizumab; 77 the causality in this case is not clear and a drug-drug interaction with trimethprimsulfamethoxazole was assumed. 77 As the experience so far with eculizumab in this rare disease is limited, physicians must be vigilant for unexpected adverse events. It is known that individuals with inherited terminal complement deficiency have an increased risk for meningococcal infections. In eculizumab-treated patients, three cases of Neisseria meningitis infections have been reported. 78 Across all PNH studies, infections did not seem to be more frequent in patients with eculizumab treatment compared with patients who received placebo. 70, 74 Eculizumab is administered between 25 and 45 minutes as an intravenous infusion according to the following dosing schedule: an induction dose of 600mg every seven (±2) days for four weeks, followed one week later by a 900mg dose, and then 900mg every 14 (±2) days. [70] [71] [72] [73] 75 A reduction in the dosing interval from 14 to 12 days was sufficient to maintain the levels of eculizumab necessary to completely block intravascular hemolysis in patients who experienced breakthrough hemolysis in the last days of the dosing interval. 75 All patients due to receive eculizumab must receive N. meningitidis vaccine at least two weeks prior to commencement of eculizumab.
Quadrivalent, conjugated meningococcal vaccines are strongly recommended. Patients must be informed about the early clinical signs of meningococcal infections and must be closely monitored.
Prevention and Treatment of Thrombosis
The most feared complications in PNH and the leading cause of diseaserelated death are thromboembolic events. 9, 13 Based on retrospective analysis, it was recommended to use primary prophylactic oral anticoagulation in patients with a large PNH cell population. 16 In this study, no thromboembolic event occurred in patients who received primary warfarin prophylaxis, whereas the 10-year risk for thrombosis was 36.5% in patients without prophylaxis.
To study the impact of long-term eculizumab treatment on thromboembolism, the event rate in the clinical trials including the open-label extension trials was compared with the pre-treatment rate in the same patients. 73 The event rate of venous or arterial thromboses prior to eculizumab was 7.37 events/100 patient-years. Given the impact of thrombosis on mortality due to PNH, 9,13 one could expect that eculizumab treatment, by decreasing the risk for thrombosis, might increase the life expectancy of these patients.
Conclusion
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